Sorry, you need to enable JavaScript to visit this website.
Skip to main content
 

Search

Johan L. J. Verbeeck, D.V.M.

JOHAN L. J. VERBEECK, D.V.M., MS.c

VICE PRESIDENT
BUSINESS DEVELOPMENT
IMMUNOLOGY

Johan Verbeeck, D.V.M., M.Sc., is Vice President, Business Development, Immunology for Johnson & Johnson Innovation, Janssen Business Development. In this role, he leads all business development activities for the Immunology Therapeutic Area and is responsible for transactions, acquisitions, scientific licensing and alliance management.

Johan brings extensive experience in licensing and external partnering to his position, which includes the identification, evaluation and successful completion of the partnership with Protagonist Therapeutics for its oral IL-23 inhibitor, and Theravance for its GI-restricted JAK inhibitor. In 1996, he joined Johnson & Johnson through Janssen Pharmaceutica in Belgium, where he worked in the Department of Animal Health and subsequently worked in Toxicology, where he became a Study Director for a multitude of small molecule development projects.

In 2005, Johan joined Tibotec, as Lead Toxicologist for the development of the company’s first two approved anti-HIV drugs. At the same time, he was Preclinical Development Leader for the first new drug in development for tuberculosis in over 40 years. For the latter program, he received the Johnson & Johnson Medal for Research and Development in 2013. In 2007, Johan became Head of Toxicology Sciences for Janssen Research & Development. He also served as Alliance Manager in the External Alliances and Business Models group.

Johan earned his D.V.M. at the University of Ghent in Belgium and his M.Sc. in Applied Toxicology at the University of Surrey in the UK. Test